HM Payson & Co’s Eidos Therapeutics, Inc. Common Stock EIDX Stock Holding History

HM Payson & Co’s Portfolio EIDX Stock Details EIDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-154	Closed	-$20K	–	1212
2020 Q4	$20K	Sell	154 -42	-21%	-$3.71K	﹤0.01%	772
2020 Q3	$10K	Buy	+196	New	+$8.81K	﹤0.01%	838

HM Payson & Co's EIDX Position: Q1 2021 in Review

HM Payson & Co sold out of Eidos Therapeutics, Inc. Common Stock (EIDX) in Q1 2021, closing a stake of 154 shares — an estimated $20K sold.

HM Payson & Co first reported a position in EIDX in Q3 2020 and held it in 2 quarters. The position peaked at $20K in Q4 2020. 0 funds tracked by Wall St. Rank hold EIDX as of Q1 2021.

HM Payson & Co reported no remaining Eidos Therapeutics, Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
HM Payson & Co sold 154 Eidos Therapeutics, Inc. Common Stock shares in Q1 2021, an estimated $20K.
HM Payson & Co first reported a position in Eidos Therapeutics, Inc. Common Stock in Q3 2020 and held it in 2 quarters.
HM Payson & Co's Eidos Therapeutics, Inc. Common Stock position peaked at $20K in Q4 2020.
0 funds tracked by Wall St. Rank held Eidos Therapeutics, Inc. Common Stock as of Q1 2021.

Based on HM Payson & Co's 13F filing for Q1 2021, filed 15 Jun 2021.